Chemomab Therapeutics Ltd. · NASDAQ:CMMB
Chemomab Therapeutics — Investor Presentation (January 2023)
35 slides from Chemomab Therapeutics's investor presentation, Jan 11, 2023
Slide 1: Pioneering Innovative Treatments for Fibro-inflammatory Diseases
e@ o< ee Chemomab THERAPEUTICS Pioneering Innovative Treatments for Fibro-inflammatory Diseases CORPORATE OVERVIEW NASDAQ: CMMB €70Z AUVANVE
Slide 2: Forward Looking Statements
Forward Looking Statements OSs This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These forward-looking statements include, among other things, statements regarding the clinical development pathway for CM-101; the future operat
Slide 3: Unique target with dual activity
@ee e< eve Chemomab Unique target* with dual activity At confluence of fibrosis & inflammation Disease-modifying potential Focus on PSC, SSc, NASH & others Two major Phase 2 read-outs next year *CCL24: Cytokine-family soluble protein target central to biology of inflammation & fibrosis CHEMOMAB THER
Slide 4: Pipeline in a Product
CM-101: Pipeline in a Product ADDRESSING FIBRO-INFLAMMATORY DISEASES WITH HIGH UNMET NEED PROGRAM CM-101 Next-Gen (Novel Targets) INDICATION © Liver Fibrosis Biomarkers Ey. enaripavso ] + Ph 2ANASH (SCA Liver Fibrosis Biomarkers) Cholangitis Diseases TBD TARGET DISCOVERY PRECLINICAL PHASE 1 PHASE 2
Slide 5: CCL24's Role in The Vicious Cycle of Inflammation and Fibrosis
CCL24’s Role in The Vicious Cycle of Inflammation and Fibrosis OSs cua Secreting Cells Z = »y 3 oes Sey 6 Epithelial Cel The Target | cers THE POWER rs P Wey wei, yy OF CCL24 causing inet pegulated Cells al pegulated Cells pel iad ° {> Dual Role in Promoting By Monocytes Fibroblasts ibrosis & ? Infl
Slide 6: Neutralizes CCL24, Breaking Vicious Cycle
CM-101 Neutralizes CCL24, Breaking Vicious Cycle OSs cM-101 te ccL24 The Antibody ke The Target T. Lo a » & ccL24 Receptor ccL24 Regulated Cells Regulated Cells O > Monocytes Fibroblasts INFLAMMATION FIBROSIS @ Qc Immune cellrecruitment Fibroblast activation ATTENUATED ATTENUATED Tissue Tissue HEALI
Slide 7: The Proof: First-in-Class CM-101 Neutralizes CCL24
The Proof: First-in-Class CM-101 Neutralizes CCL24 CM-101 Reduces In vivo Monocyte Recruitment Number of Migrated Monocytes (x1000) 10 see ae PBs ccL24 ccL24+ M101 cua [Regulated Cells Monocyt Immune cell recruitment ATTENUATED Fibroblast activation ‘ATTENUATED In balance CM-101 Inhibits Primary Fib
Slide 8: Broad, Diverse Preclinical Evidence De-risks Clinical Development
Broad, Diverse Preclinical Evidence De-risks Clinical Development CCL24 Target Validation ji Ex-vivo Patient Samples Mechanism of Action OSs EXTENSIVE EVIDENCE ... across multiple organs (liver, skin, lung etc.) Proof of Concept / Animal Models CCL24 Target Validation iat In-vivo (Knockout Animal Mo
Slide 9: Appeared Safe & Well Tolerated in Phase 1a Trial
CM-101 Appeared Safe & Well Tolerated in Phase 1a Trial = SINGLE ASCENDING DOSE STUDY CM-101 appeared safe and well tolerated up to 10 mg/kg Drug related AEs were mild with no SAEs Half-life supports 2-4 weeks dosing Dose-dependent target engagement* SC & IV formulations showed comparable target eng
Slide 10: Pipeline in a Product
CM-101: Pipeline in a Product ADDRESSING FIBRO-INFLAMMATORY DISEASES WITH HIGH UNMET NEED PROGRAM CM-101 Next-Gen (Novel Targets) INDICATION TARGET DISCOVERY PRECLINICAL PHASE 1 PHASE 2 OSs MILESTONES i Fibrosis Biomarkers Ph 1BNAFLD (IV/SC) Safety & biomarker d in NAFLD patients Data Reported 2021
Slide 11: Phase 1B Multiple Dose Safety Trial in NAFLD Patients
CM-101 Phase 1B Multiple Dose Safety Trial in NAFLD* Patients & PATIENTS: CM-101 WAS WELL-TOLERATED; DEMONSTRATED FAVORABLE TARGET ENGAGEMENT & PK Patients had NAFLD & normal liver function Multiple CM-101 IV & SC administrations appeared safe & well -tolerated Most frequently reported AEs were mild
Slide 12: Anti-Fibrotic Mechanisms Confirmed in NAFLD Patients
CM-101 Anti-Fibrotic Mechanisms Confirmed in NAFLD Patients e @& PROVIDED FOUNDATION FOR FURTHER CLINICAL TRIALS PATIENTS PK-TARGET ENGAGEMENT FIBROSIS BIOMARKERS* LIVER STIFFNESS Changes in FibroScan® Fibrosis Status PK-PD 2.5mg/kg IV Relative Change from Baseline (%4) Relative change from Baseline
Slide 13: Phase 2a Liver Fibrosis Trial in NASH Patients
CM-101 Phase 2a Liver Fibrosis Trial in NASH Patients & APPEARED SAFE & WELL TOLERATED IN NASH PATIENTS WITH F1C-F3 FIBROSIS — Primary objective: Reneaneation sofety Vist: 1 and 140 + Determine safety & tolerability of SC CM-101 in NASH oe ad poe Se eh ur uo wee Doses:! | Ill Nv SW Cw [uw Beenie ind
Slide 14: Demonstrated Favorable PK-Target Engagement Profiles
CM-101 Demonstrated Favorable PK-Target Engagement Profiles PHARMACOKI NETICS Absolute serum concentration of CM-101 60 Mean serum CM-101 TARGET ENGAGEMENT™ 5000: © CM-4101 © Placebo Average half-life 19. 2 days Drug exposure aligned with previous clinical N=12 active, 9 placebo I studies PK - Pharm
Slide 15: Reduced Individual Fibro-Inflammatory Biomarkers
CM-101 Reduced Individual Fibro-Inflammatory Biomarkers 40-7 -204 hd Change from baseline (%) PATIENTS Change in Liver Fibrosis Biomarkers Compared to Placebo © = cM101 e Placebo PROC18 CTXill TIMP1 = 205 ps.02* Ss $ 4 4 o 63 @ 25-1 . = . £ - 3 g 25> 5 oO = . ee g . 8 5 Fy ° 2 a2 0 § o4 E704 E E = l
Slide 16: Produced More Responders & Multiple Responders
CM-101 Produced More Responders & Multiple Responders* ® @& - | — PATIENTS Positive Fibrosis Biomarker Responses Proportion of CM-101 Responders by biomarker Proportion of Multiple reaching or surpassing threshold (number/%) CM-101 Responders* 100 100 p=09 32 p=.03* 80 I Placebo 2 p=.09 FI o p=007*
Slide 17: Improved Liver Stiffness Score
CM-101 Improved Liver Stiffness Score & EVIDENCE OF POSITIVE PHYSIOLOGICAL EFFECTS IN THE LIVER ean Change in Fibrosis Grade by FibroScan® (reduction in at least 1 grade) 50 p=0.16 > So @m™ CM-101 EI] Placebo w S N i) % patients = o 0 16 weeks EE 0's Grading 228585295) 952435) S135) | by FibroScan(k
Slide 18: Patients with High CCL24 at Baseline Showed Greater Biomarker Responses
Patients with High CCL24 at Baseline Showed Greater Biomarker Responses & CM-101-TREATED PATIENTS WITH HIGH CCL24 ALSO MORE LIKELY TO BE MULTIPLE RESPONDERS anon High CCL24~ PROC3 CTXII pRoc4 Timp1 Median serum CCL24 (pg/mL) at baseline % change from baseline % change from baseline % change from bas
Slide 19: Pipeline in a Product
CM-101: Pipeline in a Product ADDRESSING FIBRO-INFLAMMATORY DISEASES WITH HIGH UNMET NEED PROGRAM rT fm CM-101 INDICATION Fibrosis Biomarkers Ph 1BNAFLD (IV/SC) TARGET DISCOVERY PRECLINICAL PHASE 1 PHASE 2 Safety & biomarker d in NAFLD patients OSs MILESTONES Data Reported 2021 (Novel Targets) ccuza
Slide 20: Anti-Fibrotic Mechanisms Confirmed in Lung Injury Patients
Anti-Fibrotic Mechanisms Confirmed in Lung Injury Patients & CM-101 REDUCED INFLAMMATION/FIBROGENESIS BIOMARKERS ASSOCIATED WITH SYSTEMIC SCLEROSIS PATIENTS: Single arm, open label investigator study in 16 COVID-19 patients with severe lung injury* CM-101 Demonstrated Strong & Rapid Reductions in Bi
Slide 21: Anti-Fibrotic Mechanisms Demonstrated in Early Clinical Studies
Anti-Fibrotic Mechanisms Demonstrated in 3 Early Clinical Studies CM-101 REDUCED FIBRO-INFLAMMATORY BIOMARKERS IN NAFLD, NASH & LUNG INJURY OSs CM-101 Is Safe & Well Tolerated * AEs mostly mild; No drug-related SAEs * Consistent PK & target engagement profiles * NOADAs detected CM-101 Improved Resul
Slide 22: Pipeline in a Product
CM-101: Pipeline in a Product ADDRESSING FIBRO-INFLAMMATORY DISEASES WITH HIGH UNMET NEED OSs PROGRAM INDICATION TARGET DISCOVERY PRECLINICAL PHASE 1 PHASE 2 MILESTONES © Liver Fibrosis Biomarkers Safety & biomarker data in NAFLD patients i PAABWAELD GEC) cei safety & biomarker data in NAFLD patient
Slide 23: Primary Sclerosing Cholangitis (PSC): High Morbidity and Mortality
Primary Sclerosing Cholangitis (PSC): High Morbidity and Mortality Rare, Chronic Liver Disease OSs r 1 CHARACTERIZED BY DEVASTATING DISEASE WITH INFLAMMATION AND FIBROSIS NO APPROVED THERAPIES Affects: Bile Duct Mostly Men (2:1 Male/Female); Associated with IBD Fibrotic stricture Diagnosis: & _ Infl
Slide 24: CCL24 Plays a Key Role in PSC
CCL24 Plays a Key Role in PSC & DATA FROM PATIENT SAMPLES SUPPORTS CLINICAL RELEVANCE OF CCL24 IN PSC eae CCL24 SERUM LEVEL IN PSC PATIENTS CCL24 LEVEL IN HEALTHY VS PSC PATIENT LIVER TISSUE" Healthy Liver PSC Livers ALP > 1.5 Upper Limit of Normal cCL24 Staining CCL24 pgim! CCL24 (brown) overexpres
Slide 25: Reduces Liver Fibrosis by >80% in TAA Model
CM-101 Reduces Liver Fibrosis by >80% in TAA Model RAT MODEL LIVERS SIRIUS RED (COLLAGEN) Healthy TAA+ CM-101 TAA Fibrosis Segal-Salto etal, JHEP reports 2020 TAA-Thioacetamide 100 % FIBROSIS (SIRIUS RED STAINING) 82% reduction | TAA Taa+cMao1 (2.smg/kg) ~. ANIMAL MODELS nage Col1A1 " Col3A1 Pretbra
Slide 26: Reduces Liver Injury and Fibrosis in PSC Animal Model
CM-101 Reduces Liver Injury and Fibrosis in PSC Animal Model Rinne MDR2 MOUSE KNOCKOUT, REDUCED MACROPHAGE ATTENUATED LIVER REDUCED ABERRANT BILE NUMBER COLLAGEN DEPOSITION EPITHELIAL PROLIFERATION Mdr2 + Mdr2 + Mdr2 + 8 15: 7 i¢ é if é zi¢ = 3 é = Z 53 os. z me = Zo. = Be a Zo. 2 2 2 0. , 00. r 0.
Slide 27: Phase 2 Trial in Primary Sclerosing Cholangitis
CM-101 Phase 2 Trial in Primary Sclerosing Cholangitis RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED ENHANCED BY ADDING PATIENTS, SITES, DOSE-FINDING, OPEN LABEL EXTENSION CM-101-PSC-101* Sei giv Ge CM-101 20 mg/kg; 1.V.Q (CM-4101 10 mg/kg; 1.V.03W Gets fe) 415-Week Treatment Period fo } 33:-Week Ope
Slide 28: Systemic Sclerosis (SSc): Most Lethal Systemic Rheumatic Disease
Systemic Sclerosis (SSc): Most Lethal Systemic Rheumatic Disease OSs Rare Autoimmune Rheumatic Disease I | CHARACTERIZED BY INFLAMMATION, DEVASTATING DISEASE WITH FIBROSIS AND VASCULOPATHY NO APPROVED DISEASE MODIFYING THERAPY Affects: SKIN: LUNG INVOLVEMENT: Leading cause of death 6 © Source: Johns
Slide 29: CCL24: A Critical Node Potentiating Systemic Sclerosis
CCL24: A Critical Node Potentiating Systemic Sclerosis & PATIENT SAMPLES PATIENT SAMPLE DATA SUPPORTS THERAPEUTIC UTILITY OF BLOCKING CCL24 IN SYSTEMIC SCLEROSIS SSc Skin CCL24/CD31/DAPI CCL24/CD31/DAPI Collaboration withUniver Mora Healthy Skin CCL24 SERUM LEVELS 4000 ee 3000 ;. Serum bd cet e (8!)
Slide 30: Target Validation: CCL24 Gene Knockout Ameliorates Induced SSc
Target Validation: CCL24 Gene Knockout Ameliorates Induced SSc Rie REDUCES INDUCED SSC-LIKE INFLAMMATION & FIBROSIS IN LUNG & SKIN IN MOUSE MODEL Sse BLEOMYCIN MOUSE MODEL Immune Cell Lung Infiltration Dermal Thickness** 5000 4000 #Cells 3000 Inflating ToBAL 2000 1000 ° Dermal Thickness Compared To
Slide 31: Significantly Reduces Skin and Lung Fibrosis in Induced SSc
CM-101 Significantly Reduces Skin and Lung Fibrosis in Induced SSc ad BLEOMYCIN: INDUCED ANIMA BLEOMYCIN (SC)-INDUCED DERMAL FIBROSIS 100 Reduces skin & lung fibrosis levels 80 | = in bleomycin-induced animal models Co appr corcertator (yghert sue) Demonstrates dose dependent reduction of fibrosis B
Slide 32: Phase 2 Trial in Systemic Sclerosis
CM-101 Phase 2 Trial in Systemic Sclerosis RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED; PLAN TO INITIATE Q1 2023 patients - ieee poe Dosing 21 (Actives. : ae, Placebo) Placebo; I,V.3W (N=15) ‘ollow-Up 24-Week Treatment Period 8 24-Week Open Label Phase Ord Territories: US, Canada, UK, EU, Israe Orp
Slide 33: Experienced Management with Extensive Biopharma Experience
Experienced Management with Extensive Biopharma Experience °< ee ° Dale Pfost, PhD | Adi Mor, PhD 7 Chairman & Co-founder & e992 = p, chief Executive Officer smanname ggcemen Chief Scientific Officer 2 Don Marvin a Matthew Frankel, MD , GHD Rsscies Chief Medical Officer & (NOVARTIS Chief nancial Off
Slide 34: Unique target with dual activity
@ee e< eve Chemomab Unique target* with dual activity At confluence of fibrosis & inflammation Disease-modifying potential Focus on PSC, SSc, NASH & others Two major Phase 2 read-outs next year *CCL24: Cytokine-family soluble protein target central to biology of inflammation & fibrosis CHEMOMAB THER
Slide 35: Thank you
Thank you THERAPEUTICS
Chemomab Therapeutics — Investor Presentation (January 2023) on 6ix